Clinical Trial Update: Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ACY-241 in combination with nivolumab for unresectable non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ACY-241
• OPDIVO (nivolumab)

Snippet

Sponsor: Celgene | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: TERMINATED